{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:16:01Z","timestamp":1760242561308,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007312","name":"Cleveland Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.urology.2012.04.038","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T15:21:22Z","timestamp":1338909682000},"page":"736.e1-736.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sunitinib Malate Provides Activity Against Murine Bladder Tumor Growth and Invasion in a Preclinical Orthotopic Model"],"prefix":"10.1016","volume":"80","author":[{"given":"Eddie Shu-yin","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna E.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Larchian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren D.","family":"Heston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2012.04.038_bib1","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2012.04.038_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2012.04.038_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","article-title":"Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer","volume":"175","author":"Xia","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2012.04.038_bib6","first-page":"5281","article-title":"Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer","volume":"57","author":"Crew","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2012.04.038_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1078-1439(03)00015-2","article-title":"The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression","volume":"22","author":"Yang","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0022-5347(05)65752-7","article-title":"Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer","volume":"166","author":"Bernardini","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2012.04.038_bib9","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.juro.2009.08.020","article-title":"Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model","volume":"182","author":"Chan","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2012.04.038_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.urology.2009.06.047","article-title":"Transabdominal micro-ultrasound imaging of bladder cancer in a mouse model: a validation study","volume":"75","author":"Patel","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2012.04.038_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199101033240101","article-title":"Tumor angiogenesis and metastasis\u2014correlation in invasive breast carcinoma","volume":"324","author":"Weidner","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2012.04.038_bib12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/jnci\/87.21.1603","article-title":"Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis","volume":"87","author":"Bochner","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2012.04.038_bib13","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.juro.2011.02.047","article-title":"Initial application of in vivo targeted contrast-enhanced micro-ultrasound imaging for measuring intra-tumoral perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model","volume":"185","author":"Chan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2012.04.038_bib14","first-page":"4355","article-title":"Angiogenesis, angiogenic factor expression and prognosis of bladder cancer","volume":"21","author":"Streeter","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urology.2012.04.038_bib15","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib16","first-page":"188","article-title":"Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer","volume":"5","author":"Kupsch","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.urology.2012.04.038_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-006-0257-y","article-title":"Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma","volume":"59","author":"Carter","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urology.2012.04.038_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000224877","article-title":"Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer","volume":"83","author":"Nakanishi","year":"2009","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2012.04.038_bib19","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.urology.2012.04.038_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.urolonc.2008.03.017","article-title":"Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model","volume":"27","author":"Sonpavde","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urolonc.2008.06.001","article-title":"Preoperative hydronephrosis as an indicator of survival after radical cystectomy","volume":"27","author":"Chapman","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib22","first-page":"2583","article-title":"Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer","volume":"9","author":"Goddard","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2012.04.038_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-5347(01)64485-9","article-title":"Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer","volume":"158","author":"Asakura","year":"1997","journal-title":"J Urol"},{"issue":"suppl 1","key":"10.1016\/j.urology.2012.04.038_bib24","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.acra.2005.02.021","article-title":"Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies","volume":"12","author":"Broillet","year":"2005","journal-title":"Acad Radiol"},{"key":"10.1016\/j.urology.2012.04.038_bib25","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-09-0731","article-title":"Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2012.04.038_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1148\/radiol.2462070536","article-title":"US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice","volume":"246","author":"Willmann","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.urology.2012.04.038_bib27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.7863\/jum.2007.26.11.1575","article-title":"Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography","volume":"26","author":"Lyshchik","year":"2007","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.urology.2012.04.038_bib28","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2012.04.038_bib29","first-page":"1691","article-title":"Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1\/2 phosphorylation","volume":"40","author":"Takeuchi","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urology.2012.04.038_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4111\/kju.2011.52.1.55","article-title":"Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells","volume":"52","author":"Yoon","year":"2011","journal-title":"Korean J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429512004797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429512004797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:55:36Z","timestamp":1758765336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429512004797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0090429512004797"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2012.04.038","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib Malate Provides Activity Against Murine Bladder Tumor Growth and Invasion in a Preclinical Orthotopic Model","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2012.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}